The Search for Optimal Treatment in Relapsed and Refractory Acute Myeloid Leukemia

Abstract

Despite the significant progress in the treatment of AML during the last 5-10 years, 20-40% of patients still do not achieve remission with standard induction therapy. In addition, 50-70% of patients in CR are likely to relapse. A major limitation of successful AML therapy is intrinsic or acquired drug resistance. Several pharmacological inhibitors of mechanisms inducing chemoresistance in leukemic cells have been investigated. New cytotoxic drugs, agents with novel mechanisms of action, and new treatment strategies are currently being investigated. The management of refractory or relapsed AML patients is reviewed in this study.

• Acute Myeloid Leukemia
• Refractory
• Relapsed Leukemia
• Drug Resistance
• Chemotherapy
• Immunotherapy
• Stem Cell Transplantation